Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure
This randomized, double-blind, placebo-controlled trial investigated the effects of the oral GH secretagogue MK-677 (25 mg daily) on GH secretion, body composition, and energy expenditure in 24 healthy obese men aged 18–50. Over 8 weeks, MK-677 significantly increased serum IGF-I levels by approximately 40% and GH secretion, as measured by